Monte Rosa Therapeutics Quarterly Balance Sheet
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Monte Rosa Therapeutics financial position
As of Jun 30, 2026, Monte Rosa Therapeutics reported total assets of $691.2 million, up 92.2% from a year earlier against total liabilities of $203.9 million. Shareholders' equity stood at $487.3 million, or 70.5% of assets. The company held $90.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.58, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Monte Rosa Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 90.10M | 159.86M | 129.88M | 208.34M | 69.43M | 78.53M | 224.25M | 125.58M | 108.85M | 99.75M | 128.10M | 59.05M |
| Receivables | — | — | — | — | — | — | — | — | 9.00M | — | — | — |
| Total Current Assets | 631.41M | 677.55M | 393.19M | 401.82M | 299.46M | 332.28M | 377.44M | 251.21M | 277.90M | 199.04M | 236.21M | 182.91M |
| Property, Plant & Equipment | 29.93M | 28.41M | 25.99M | 27.60M | 29.05M | 29.34M | 29.48M | 31.44M | 33.25M | 34.04M | 33.80M | 34.99M |
| Total Assets | 691.16M | 736.43M | 448.66M | 459.84M | 359.59M | 393.20M | 438.73M | 315.08M | 344.11M | 266.75M | 303.75M | 252.10M |
| Accounts Payable | 7.15M | 7.90M | 3.55M | 14.51M | 5.58M | 6.49M | 17.21M | 3.98M | 6.47M | 6.83M | 11.15M | 5.50M |
| Total Current Liabilities | 59.66M | 71.04M | 64.21M | 61.44M | 41.85M | 59.22M | 156.95M | 41.64M | 42.35M | 41.29M | 46.59M | 22.61M |
| Total Liabilities | 203.88M | 214.51M | 215.60M | 214.00M | 91.51M | 118.04M | 215.80M | 109.62M | 119.44M | 114.23M | 124.50M | 67.58M |
| Shareholders' Equity | 487.28M | 521.92M | 233.06M | 245.84M | 268.08M | 275.16M | 222.94M | 205.46M | 224.67M | 152.52M | 179.25M | 184.52M |
| Retained Earnings | -565.11M | -521.72M | -477.21M | -431.08M | -404.00M | -391.70M | -438.59M | -452.02M | -428.17M | -397.86M | -365.89M | -332.64M |
| Net Cash (Debt) | 90.10M | 159.86M | 129.88M | 208.34M | 69.43M | 78.53M | 224.25M | 125.58M | 108.85M | 99.75M | 128.10M | 59.05M |
| Shares Outstanding | 85.23M | 84.32M | 65.54M | 61.79M | 61.72M | 61.51M | 61.51M | 61.38M | 61.33M | 50.20M | 50.14M | 50.07M |
This table shows 12 quarterly periods of Monte Rosa Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow GLUE's reporting calendar. What is a balance sheet?